CV Therapeutics and Astellas receive FDA approval for Lexiscan injection

Lexiscan is claimed to be the first A2A adenosine receptor agonist shown to be safe and effective as a pharmacologic stress agent in myocardial perfusion imaging (MPI) studies. Lexiscan is delivered as a rapid bolus (approximately 10 seconds) with no dose adjustment required for body weight.

Yoshihiko Hatanaka, president and CEO of Astellas Pharma US, said: “We are extremely pleased that the FDA has approved Lexiscan, an exciting new option for diagnosing coronary artery disease in patients who cannot undergo an exercise stress test. We are preparing to launch Lexiscan soon after this approval in order to provide clinicians with this important new option for patients who need pharmacologic stress agents for MPI studies.”